Table 3.

Multivariable logistic regression: identifying factors associated with erectile dysfunction

Characteristic	OR	95% CI	P-value
Age (years)
<30	Ref
30–39	0.31	0.09–1.01	.06
40–49	0.41	0.12–1.29	.13
50–59	0.43	0.10–1.63	.22
60+	1.77	0.59–5.51	.32
Race
White	Ref
Black/African	2.20	0.61–7.40	.21
Hispanic/Latino	8.51	0.28–2.36	.76
Other	0.83	0.24–2.56	.75
Relationship status
Married	Ref
In a relationship	1.33	0.49–3.45	.56
Single	3.21	1.46–7.28	.004∗∗
Home region
US West	Ref
International	2.07	0.71–5.95	.18
US Midwest	0.70	0.18–2.41	.59
US Northeast	0.91	0.35–2.31	.84
US South	0.64	0.22–1.73	.39
Tobacco smoking history
Never smoker	Ref
Current smoker	2.25	0.79–6.46	.13
Former smoker	8.50	0.40–1.84	.68
# of PCP visits in the last 3 months
0	Ref
1	1.41	0.65–3.07	.38
2+	3.35	1.36–8.30	.008∗∗
Total comorbidities
0	Ref
1	1.26	0.51–3.19	.62
2	1.91	0.69–5.26	.21
3+	1.84	0.66–5.23	.24
Cannabis use frequency (continuous)∗	0.81	0.67–0.98	.03∗
Cannabis chemovar
THC dominant	Ref
CBD:THC 1:1	1.17	0.52–2.57	.7
CBD dominant	0.68	0.18–2.36	.55
The primary method of consumption
Smoking flower	Ref
Edibles	0.89	0.16–3.66	.88
Smoking concentrates or extracts	1.82	0.49–6.00	.34
Tincture or oils	1.24	0.31–4.52	.75
Vaping	0.86	0.32–2.23	.77
Other	4.85	0.95–24.28	.053

Comorbidities assessed included hypertension, diabetes, heart disease, arthritis, lung disease, kidney disease, thyroid disease, hypercholesterolemia, cancer, neurologic disease, liver disease, depression, and anxiety.

US = the United States; PCP = primary care physician, THC = tetrahydrocannabinol, CBD = cannabidiol.

∗P < .05, ∗∗P < .01, ∗∗∗P < .001.

^∗One-unit increase translates to one additional time using cannabis per week.